Craft

Swedish Orphan Biovitrum

Stock Price

KR345.6

2024-10-29

Market Capitalization

KR118.7 B

2024-10-29

Revenue

KR22.1 B

FY, 2023

Swedish Orphan Biovitrum Summary

Company Summary

Overview
Swedish Orphan Biovitrum (Sobi) is an integrated biotechnology company that researches, develops, manufactures, and sells treatments in the areas of hematology, immunology, and specialty care. It offers factor replacement treatments Alprolix and Elocta/Eloctate. In addition, the company provides Aspaveli/Empaveli, Doptelet, Gamifant, Kineret, Orfadin, Synagis, and other medicines such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra.
Type
Public
Status
Active
Founded
2010
HQ
Solna, SE | view all locations
Website
https://www.sobi.com/en
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Guido Oelkers

    Guido Oelkers, Chief Executive Officer

    • Henrik Stenqvist

      Henrik Stenqvist, Chief Financial Officer

      • Sofiane Fahmy
      • Duane H. Barnes

        Duane H. Barnes, Head of North America

      LocationsView all

      35 locations detected

      • Solna, Stockholms län HQ

        Sweden

        Tomtebodavägen 23a

      • Waltham, MA

        United States

        77 4th Avenue, 3rd Floor

      • Sydney, NSW

        Australia

        Level 22, 44 Market St

      • Wien, Wien

        Austria

        Dorotheergasse 6-8/L, Top 24

      • Zaventem, Vlaams Gewest

        Belgium

        Luchthaven Brussel Nationaal 1K

      • Sofia, Sofia City Province

        Bulgaria

        30-32 Gen. E.I. Totleben blvd, fl. 2

      and 29 others

      Swedish Orphan Biovitrum Financials

      Summary Financials

      Revenue (Q3, 2024)
      kr6.9B
      Gross profit (Q3, 2024)
      kr5.6B
      Net income (Q3, 2024)
      kr1.5B
      Cash (Q3, 2024)
      kr594.0M
      EBIT (Q3, 2024)
      kr2.0B
      Enterprise value
      $136.0B

      Footer menu